Testing two JAK inhibitor medicines in healthy adults
Treatments studied
This early-stage study tests how two experimental medicines (povorcitinib by mouth and ruxolitinib cream on skin) work in healthy volunteers. Researchers will measure how these drugs move through your body and affect your skin to learn if they're safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old and in generally good health with no serious heart, lung, kidney, or other organ problems
- Your body mass index (weight relative to height) is between 18.0 and 30.5
- You have no history of autoimmune disease, cancer (except treated skin cancer), or active infections like TB or HIV
- You are willing to avoid pregnancy or fathering children during the study
- You cannot take most other medications, including birth control pills, strong supplements, or grapefruit products for set periods
- You must be willing to have skin biopsies (small tissue samples) taken and avoid sun, swimming, and heavy exercise for 2 weeks after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (INCA033989) given as a shot or IV in healthy adults to see how the body processes it and if it's safe.
This trial tests the drug ruxolitinib (a JAK inhibitor) for people with inclusion body myositis (IBM), a progressive muscle disease. It aims to see if ruxolitinib can help slow muscle weakness and improve function.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
This trial is testing a new study drug called LAD106 to see if it is safe in healthy adults. It helps researchers learn how the drug works in the body before moving on to patients with a specific condition.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.